It’s a penny stock, so I would not expect a lot of US based news coverage. Conferences and analysts are hard to come by for a penny stock as well. Medical conferences, medical publications and similar are not hung up on the penny stock issue because they do not typically have to reference the company at all. So I will expect more of that kind of coverage. But even then, you have some quite astonishing results published in Nature and narry a mention in US popular press. Meanwhile if one person lives beyond 1 year with a treatment that is not even in trials in Australia, you see a slew of “breakthrough” headlines. This goes to show how artificial limits on media, put in place for good reasons but also senselessly followed, tend to not fully inform their audiences. They are trying NOT to be caught in securities litigation or promote stock frauds which was a problem at one time, but is not as much a problem now. Because they do not report on such companies, it has really not been an issue for mainstream media. But it also leaves those legitimate companies out in the cold. This gives room for the AF’s and similar to monopolize the small, drug development sector.
Market Data 
Markets 
